

| General Information   |   |
|---|---|
| Ministerial Decision Type   | Miscellaneous   |
| Report Title  | Amendment to the Prescribed List as of 1 Aug 2025                 |
| Minister  | Social Security   |
| Signatory   | Minister  |
| Lead Department   | Strategic Policy, Planning and Performance (SP3)                  |
| Lead Directorate  | Public Policy (SP3)   |
| Ministerial Decision Summary: Public or <a href="#">Absolutely/Qualified</a> Exempt   | Public<br>Select if more than one Absolutely/Qualified Exemption. |
| Date decision made if different to date 'Ministerial Decision Summary' signed.  | Select date.  |
| Report and Supplemental Report Details  |   |
| Report Author   | Prescribing Advisor   |
| Date of Report  | 17/06/2025  |
| Supplementary Report Title<br><i>(If applicable)</i>  | SD Prescribed list as of 1 Aug 2025                               |
| Supplementary Report Author<br><i>(If applicable)</i>   | Prescribing Advisor   |
| Date of Supplementary Report<br><i>(If applicable)</i>  | 17/06/2025  |
| Ministerial Decision Report: Public or <a href="#">Absolutely/Qualified</a> Exempt  | Public<br>Select if more than one Absolutely/Qualified Exemption. |
| Relevant Case/Application/URN<br><i>(Only complete if making a decision related to an appeal where appropriate or allowed under legislation/case/application)</i> | Insert Relevant Case/Application.                                 |
| Relevant Proposition Number<br><i>(Only complete if presenting Comments or if lodging an Amendment)</i>   | Insert P. number.   |
| Relevant Scrutiny Report<br><i>(Only complete if presenting a ministerial response)</i>   | Insert S.R. number.   |
| Associated Law(s) and/or Subordinate Legislation  | Health Insurance (Jersey) Law 1967                                |
| Action required if recommendation agreed  | Department to take necessary action.                              |

|                       |  |
|-----------------------|--|
| Resource Implications | There are no new financial and/or staffing implications. |
|-----------------------|--|

### **Introduction**

Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee (PBAC), the Minister decided to make amendments to the Prescribed List with effect from 1 August 2025

### **Recommendation**

Other

Only insert text if 'Other' selected above.

The Minister accepted recommendations from the PBAC in respect of the following additions and deletions.

#### **1. Additions**

The following products provide additional strengths or alternative formulations to medicines already included in the Prescribed List. Their use will replace that of an existing product, often providing greater convenience for patients, for example who have difficulty swallowing tablets and need a liquid or soluble form. Overall, use of these products is expected to be very low and cost impact minimal.

- a. Tamoxifen 10mg/5ml oral solution sugar free – alternative formulation
- b. Fludrocortisone 50mcg tablets – additional strength
- c. Tacrolimus 750 microgram capsules (Adoport) - additional strength
- d. Calcium & vitamin D effervescent products (Cacit D3 sachets, Adcal-D3 Dissolve tablets)– alternative formulations
- e. Mesalazine 1.6g gastro-resistant tablets (Octasa 1600mg MR) - additional strength
- f. Nitrofurantoin 50mg and 100mg capsules – alternative (less expensive) formulation
- g. Levetiracetam 1g tablets – additional strength
- h. Ropinirole 3mg and 6mg modified-release tablets – additional strengths
- i. Ethinylestradiol 35microgram / Norethisterone 500microgram tablets – additional strength
- j. Aciclovir 200mg / 400mg / 800mg dispersible tablets – alternative (less expensive) formulation

#### **2. Deletions (to take effect from 1 January 2026)**

The Committee recommended removal of the following products from the Prescribed List that are either discontinued or rarely used. Alternative products are available on the List where needed.

- a. Salbutamol 500micrograms/1ml solution for injection ampoules
- b. Salbutamol 5mg/5ml solution for infusion ampoules
- c. Insulin isophane biphasic porcine 30/70 100units/ml suspension for injection 10ml vials (Brand: Hypurin Porcine 30/70 Mix)
- d. Insulin isophane biphasic porcine 30/70 100units/ml suspension for injection 3ml cartridge
- e. Exenatide 5micrograms/0.02ml solution for injection 1.2ml pre-filled disposable device
- f. Exenatide 10micrograms/0.04ml solution for injection 2.4ml pre-filled disposable device
- g. Cu-Safe® T300
- h. Mini TT 380® Slimline

- i. Multi-Safe® 375 Short Stem
- j. Cyanocobalamin 1mg/1ml solution for injection ampoules
- k. Aveeno Lotion
- l. Aveeno daily moisturising body cleaning oil
- m. Pneumococcal polysaccharide vaccine solution for injection 0.5ml vials

**3. Other recommended changes to the Prescribed List from 1 October 2025**

- a. **Amorolfine** 5% medicated nail lacquer – a generic product now available so recommend change entry in Prescribed List to ‘Generic Only’
- b. **Premarin** (conjugated oestrogens) – the Premarin brand is discontinued but a generic product is available so recommend change entry in Prescribed List to ‘Generic Only’
- c. Azelastine 137micrograms/dose / Fluticasone 50micrograms/dose nasal spray (**Dymista**) – a generic product now available so recommend change entry in Prescribed List to ‘Generic Only’
- d. **Otomize** (Dexamethasone/ Neomycin sulfate/ Acetic acid ear spray) – the Otomize brand is discontinued but a generic product is available so recommend change entry in Prescribed List to ‘Generic Only’

**Financial impact**

The products for addition to the Prescribed List are all additional strengths or alternative forms of medicines already included in the List. Some are more expensive than existing options and others are less expensive, but the low volumes expected to be prescribed mean that the overall cost impact is likely to be cost neutral.

Recommendations for removal from the List are not expected to have a material impact on overall expenditure since alternatives are available at broadly similar cost.